Peripheral Evolution of Tanshinone IIA and Cryptotanshinone for Discovery of a Potent and Specific NLRP3 Inflammasome Inhibitor

IF 6.8 1区 医学 Q1 CHEMISTRY, MEDICINAL Journal of Medicinal Chemistry Pub Date : 2025-01-23 DOI:10.1021/acs.jmedchem.4c02648
Wenqi Zhu, Xiaodong Bao, Yuyan Yang, Muqiong Xing, Sijie Xiong, Siyu Chen, Yongxin Zhong, Xueping Hu, Qianrang Lu, Kairong Wang, Qi Ling, Sunliang Cui
{"title":"Peripheral Evolution of Tanshinone IIA and Cryptotanshinone for Discovery of a Potent and Specific NLRP3 Inflammasome Inhibitor","authors":"Wenqi Zhu, Xiaodong Bao, Yuyan Yang, Muqiong Xing, Sijie Xiong, Siyu Chen, Yongxin Zhong, Xueping Hu, Qianrang Lu, Kairong Wang, Qi Ling, Sunliang Cui","doi":"10.1021/acs.jmedchem.4c02648","DOIUrl":null,"url":null,"abstract":"Natural products (NPs) continue to serve as an invaluable source in drug discovery, and peripheral evolution of NPs is a highly efficient evolution strategy. Herein, we describe a unified “methyl to amide” peripheral evolution of Tanshinone IIA and Cryptotanshinone for discovery of NLRP3 inflammasome inhibitors. There were 54 compounds designed and prepared, while the chemoinformatic analysis revealed that these evolved NP analogues occupy a unique chemical space. Biological evaluation identified <b>5m</b> as an NLRP3 inflammasome inhibitor, and <b>5m</b> could directly bind to the NACHT domain of the NLRP3 protein and block the interaction of NLRP3 and ASC, thus suppressing ASC oligomerization and NLRP3 inflammasome assembly. Molecular dynamic stimulations revealed that the amide moiety played a vital role in the binding mode. Moreover, <b>5m</b> exhibited therapeutical efficacy in sepsis and the NASH mouse model. In conclusion, this protocol provides a new vision of NPs’ peripheral evolution and a novel NLRP3 inflammasome inhibitor.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"5 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.4c02648","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Natural products (NPs) continue to serve as an invaluable source in drug discovery, and peripheral evolution of NPs is a highly efficient evolution strategy. Herein, we describe a unified “methyl to amide” peripheral evolution of Tanshinone IIA and Cryptotanshinone for discovery of NLRP3 inflammasome inhibitors. There were 54 compounds designed and prepared, while the chemoinformatic analysis revealed that these evolved NP analogues occupy a unique chemical space. Biological evaluation identified 5m as an NLRP3 inflammasome inhibitor, and 5m could directly bind to the NACHT domain of the NLRP3 protein and block the interaction of NLRP3 and ASC, thus suppressing ASC oligomerization and NLRP3 inflammasome assembly. Molecular dynamic stimulations revealed that the amide moiety played a vital role in the binding mode. Moreover, 5m exhibited therapeutical efficacy in sepsis and the NASH mouse model. In conclusion, this protocol provides a new vision of NPs’ peripheral evolution and a novel NLRP3 inflammasome inhibitor.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
丹参酮IIA和隐丹参酮的外周进化发现一种有效的特异性NLRP3炎症小体抑制剂
天然产物(NPs)继续作为药物发现的宝贵来源,而NPs的外周进化是一种高效的进化策略。在此,我们描述了丹参酮IIA和隐丹参酮在NLRP3炎性体抑制剂发现过程中统一的“甲基到酰胺”外周进化。设计并制备了54个化合物,化学信息学分析表明,这些进化的NP类似物占据了独特的化学空间。生物学评价鉴定5m为NLRP3炎性小体抑制剂,5m可直接结合NLRP3蛋白的NACHT结构域,阻断NLRP3与ASC的相互作用,从而抑制ASC寡聚化和NLRP3炎性小体的组装。分子动力学刺激表明酰胺部分在结合模式中起着至关重要的作用。此外,5m在脓毒症和NASH小鼠模型中表现出治疗效果。总之,该方案为NPs的外周进化和新型NLRP3炎症小体抑制剂提供了新的视角。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry 医学-医药化学
CiteScore
4.00
自引率
11.00%
发文量
804
审稿时长
1.9 months
期刊介绍: The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents. The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.
期刊最新文献
Tubulin Zone Occupancy by PDB-Deposited Colchicine Binding Site Inhibitors. Synthesis and Preclinical Evaluation of 68Ga-Labeled Radiotracers for Monitoring PD-L1 Expression in Tumors. Issue Publication Information Issue Editorial Masthead From Vaccines to Therapeutics: The Need for Distinct mRNA-LNP Design Principles
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1